
## Aaron M Lebeau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8073127/publications.pdf Version: 2024-02-01



AADON MIEREALL

#	Article	IF	CITATIONS
1	Structural Characterization of a Minimal Antibody against Human APOBEC3B. Viruses, 2021, 13, 663.	1.5	2
2	The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. ELife, 2021, 10, .	2.8	42
3	Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth. Cancer Immunology Research, 2021, 9, 1270-1282.	1.6	9
4	Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1054-1064.	3.2	15
5	Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography. Clinical Cancer Research, 2020, 26, 4882-4891.	3.2	32
6	PEG10 Promoter–Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer. Cancer Research, 2019, 79, 5668-5680.	0.4	7
7	Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma. Bioconjugate Chemistry, 2019, 30, 1466-1476.	1.8	12
8	The identification of a novel antibody for CD133 using human antibody phage display. Prostate, 2018, 78, 981-991.	1.2	9
9	The Molecular Imaging of Natural Killer Cells. Molecular Imaging, 2018, 17, 153601211879481.	0.7	16
10	The role of CD133 in cancer: a concise review. Clinical and Translational Medicine, 2018, 7, 18.	1.7	257
11	Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase <i>AMACR</i> promoter for the molecular imaging of prostate cancer. Oncotarget, 2018, 9, 36693-36704.	0.8	4
12	The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach. Scientific Reports, 2017, 7, 1424.	1.6	33
13	Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Research and Treatment, 2017, 49, 1140-1152.	1.3	68
14	Protease-Activated Pore-Forming Peptides for the Treatment and Imaging of Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 659-668.	1.9	10
15	Imaging Active Urokinase Plasminogen Activator in Prostate Cancer. Cancer Research, 2015, 75, 1225-1235.	0.4	25
16	Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nature Communications, 2015, 6, 8448.	5.8	37
17	Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance. Theranostics, 2014, 4, 267-279.	4.6	31
18	Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer. Cancer Research, 2013, 73, 2070-2081.	0.4	83

Aaron M Lebeau

#	Article	IF	CITATIONS
19	Imaging a functional tumorigenic biomarker in the transformed epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 93-98.	3.3	41
20	Antagonistic Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibodies Significantly Inhibit uPAR-mediated Cellular Signaling and Migration. Journal of Biological Chemistry, 2010, 285, 26878-26888.	1.6	51
21	Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics, 2009, 8, 1378-1386.	1.9	138
22	Prostate-Specific Antigen Is a "Chymotrypsin-like―Serine Protease with Unique P1 Substrate Specificity. Biochemistry, 2009, 48, 3490-3496.	1.2	42